Immunic, Inc. (IMUX)
Market Cap | 103.59M |
Revenue (ttm) | n/a |
Net Income (ttm) | -97.92M |
Shares Out | 90.08M |
EPS (ttm) | -1.83 |
PE Ratio | n/a |
Forward PE | n/a |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 439,120 |
Open | 1.130 |
Previous Close | 1.120 |
Day's Range | 1.071 - 1.190 |
52-Week Range | 0.945 - 3.110 |
Beta | 1.83 |
Analysts | Strong Buy |
Price Target | 8.50 (+639.13%) |
Earnings Date | Aug 1, 2024 |
About IMUX
Immunic, Inc., a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical trial, for treatment of multiple sclerosis, including relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis. The company is also developing IMU-856, which is entering Phase 2 clinical trial, for the restoration of the intestinal barrier function i... [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to 2 analysts, the average rating for IMUX stock is "Strong Buy." The 12-month stock price forecast is $8.5, which is an increase of 639.13% from the latest price.
News
![](https://cdn.snapi.dev/images/v1/5/y/press5-2449351.jpg)
Immunic to Participate in Industry and Scientific Conferences in June
NEW YORK , May 28, 2024 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory ...
![](https://cdn.snapi.dev/images/v1/d/z/press6-2417427.jpg)
Immunic, Inc. Reports First Quarter 2024 Financial Results and Provides Corporate Update
– Substantially Bolstered Balance Sheet Through a Three-Tranche Private Placement Totaling Up to $240 Million, Extending Cash Runway Into the Third Quarter of 2025, Based on Initial $80 Million Tranch...
![](https://cdn.snapi.dev/images/v1/h/i/press6-2411425.jpg)
Immunic to Participate in Investor and Scientific Conferences in May
NEW YORK , May 6, 2024 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory ...
![](https://cdn.snapi.dev/images/v1/p/r/conf14-2402148.jpg)
Immunic, Inc. to Announce Financial Results for the First Quarter Ended March 31, 2024, and Provide Corporate Update
– Webcast to be Held at 8:00 am ET on May 8, 2024 – NEW YORK , May 1, 2024 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered,...
![](https://cdn.snapi.dev/images/v1/s/a/press6-2399124.jpg)
Immunic Announces Publication of Extended Data From Phase 2 EMPhASIS Trial of Vidofludimus Calcium in Relapsing-Remitting Multiple Sclerosis in the Peer Reviewed Journal, Neurology® Neuroimmunology & Neuroinflammation
– 30 mg and 45 mg Daily Doses of Vidofludimus Calcium Suppressed Development of Gadolinium-Enhancing Lesions by 78% and 74% Compared to Pooled Placebo at 24 Weeks – – Improvements in Serum Neurofilame...
![](https://cdn.snapi.dev/images/v1/r/j/conf11-2355929.jpg)
Immunic to Host MS R&D Day and Participate in Investor Conferences in April
NEW YORK , April 4, 2024 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammator...
![](https://cdn.snapi.dev/images/v1/m/3/press11-2332585.jpg)
Immunic Receives Notice of Allowance for Composition-of-Matter Patent of a Specific Polymorph of Vidofludimus Calcium in the United States
– Patent Will Also Cover a Related Method of Production of the Material – – Fourth U.S. Patent Directed to Use of Vidofludimus Calcium in Multiple Sclerosis – – Multilayered Intellectual Property Stra...
![](https://cdn.snapi.dev/images/v1/t/u/press4-2312664.jpg)
Immunic to Participate in Investor and Scientific Conferences in March
NEW YORK , March 7, 2024 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammator...
![](https://cdn.snapi.dev/images/v1/e/j/press4-2300612.jpg)
Immunic Presents Data From Phase 2 CALLIPER and CALVID-1 Trials of Vidofludimus Calcium at the ACTRIMS Forum 2024
NEW YORK , Feb. 29, 2024 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammator...
![](https://cdn.snapi.dev/images/v1/h/a/press6-2288003.jpg)
Immunic, Inc. Reports Year End 2023 Financial Results and Provides Corporate Update
– Significantly Strengthened Balance Sheet in January 2024 with Execution of Three-Tranche Private Placement of up to $240 Million, Extending Cash Runway Into the Third Quarter of 2025 Based on Initia...
![](https://cdn.snapi.dev/images/v1/n/k/conf3-2277570.jpg)
Immunic, Inc. to Announce Financial Results for the Year Ended December 31, 2023, and Provide Corporate Update
– Webcast to be Held at 8:00 am ET on February 22, 2024 – NEW YORK , Feb. 15, 2024 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally admi...
![](https://cdn.snapi.dev/images/v1/b/e/press14-2254894.jpg)
Immunic to Participate in Investor and Scientific Conferences in February
NEW YORK , Feb. 1, 2024 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory...
![](https://cdn.snapi.dev/images/v1/c/7/press5-2217856.jpg)
Immunic Highlights 2023 Accomplishments and Upcoming Milestones
– Evidence for Neuroprotective Activity of Vidofludimus Calcium from Phase 2 CALLIPER Interim Analysis , Consistent Across the Entire Progressive Multiple Sclerosis Population and All Subtypes – – Pha...
![](https://cdn.snapi.dev/images/v1/s/t/press4-2217850.jpg)
Immunic, Inc. Announces Private Placement of up to $240 Million
NEW YORK , Jan. 5, 2024 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX) ("Immunic" or the "Company"), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapi...
![](https://cdn.snapi.dev/images/v1/z/g/press18-2166692.jpg)
Immunic Receives Notice of Allowance for United States Patent Protecting Vidofludimus Calcium's Dosing Regimens in Multiple Sclerosis
– Fundamental New Patent Covers Treatment of Multiple Sclerosis Into 2038 and Beyond – – Third U.S. Patent Directed to Use of Vidofludimus Calcium in Multiple Sclerosis – – Multilayered Intellectual P...
![](https://cdn.snapi.dev/images/v1/8/e/press2-2156312.jpg)
Immunic, Inc. Reports Third Quarter 2023 Financial Results and Provides Corporate Update
– Positive Interim Analysis from Phase 2 CALLIPER Trial Showed Improvements in Serum Neurofilament Light Chain for Vidofludimus Calcium, Consistent Throughout the Overall Progressive Multiple Sclerosi...
![](https://cdn.snapi.dev/images/v1/g/b/conf20-2143416.jpg)
Immunic to Announce Financial Results for the Third Quarter Ended September 30, 2023, and Provide Corporate Update
– Webcast to be Held at 8:00 am ET on November 14, 2023 – NEW YORK , Nov. 7, 2023 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally admini...
![](https://cdn.snapi.dev/images/v1/u/x/press19-2135416.jpg)
Immunic Receives Notice of Allowance for United States Patent Protecting the Treatment of Relapsing Multiple Sclerosis with Vidofludimus and Its Salts
NEW YORK , Nov. 2, 2023 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory ...
![](https://cdn.snapi.dev/images/v1/c/e/press7-2122110.jpg)
Immunic to Participate in Scientific and Industry Conferences in November
NEW YORK , Oct. 26, 2023 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammator...
![](https://cdn.snapi.dev/images/v1/n/o/press8-2104114.jpg)
Immunic Presents Data From Phase 2 CALDOSE-1 Trial of Vidofludimus Calcium in Ulcerative Colitis at the United European Gastroenterology Week 2023
NEW YORK , Oct. 16, 2023 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammator...
![](https://cdn.snapi.dev/images/v1/r/s/press9-2103700.jpg)
Immunic Presents Data From Phase 1b Clinical Trial of IMU-856 in Celiac Disease at the United European Gastroenterology Week 2023
NEW YORK , Oct. 15, 2023 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammator...
![](https://cdn.snapi.dev/images/v1/k/t/press18-2098256.jpg)
Immunic Presents Data From Phase 2 EMPhASIS Trial of Vidofludimus Calcium in Relapsing-Remitting Multiple Sclerosis at MSMilan2023: The 9th Joint ECTRIMS-ACTRIMS Meeting
– Improvement in Serum Neurofilament Light Chain (NfL) Observed in Both Treatment Arms of Vidofludimus Calcium Over Placebo – – NfL Effect Consistent With Recently Released Data from Separate, Phase 2...
![](https://cdn.snapi.dev/images/v1/f/v/press12-2095736.jpg)
Immunic Reports Positive Interim Data from Phase 2 CALLIPER Trial of Vidofludimus Calcium in Progressive Multiple Sclerosis
– 24-Week Data from First Half of Patients Shows Improvements in Biomarker NfL, Consistent Throughout the Overall Progressive Multiple Sclerosis Population as well as All Subtypes – – NfL Effect in N...
![](https://cdn.snapi.dev/images/v1/u/u/press15-2088998.jpg)
Immunic to Participate in Scientific Conferences in October
NEW YORK , Oct. 4, 2023 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory ...
![](https://cdn.snapi.dev/images/v1/5/u/conf12-2050803.jpg)
Immunic to Participate in Industry and Investor Conferences in September
NEW YORK , Sept. 6, 2023 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammator...